🇺🇸

US SEC Filing Intelligence

· monthly

US Pre-Market SEC Filings Roundup — April 29, 2026

Overnight SEC filings reveal mixed Q1 2026 earnings across 50 companies, with standout revenue growth in AI/tech (Teradyne +87% YoY, Bloom Energy +130% YoY) and industrials (Constellium +24% YoY), but margin pressures in consumer/retail (Stanley Black & Decker EBITDA margin -50 bps, Yum China SSS flat) and healthcare (Humana Adjusted EPS -10.9% YoY). Portfolio-level trends show 18/25 reporting companies with YoY revenue growth averaging +25%, but only 9/25 with margin expansion (avg +50 bps where positive); capital returns strong via buybacks ($2.8B Visa, $20M SiteOne) and dividends. M&A momentum builds with approvals (Mission Produce/Calavo closing July 2026, Woori/Tongyang Aug 11), while regulatory resolutions (RYVYL SEC settlement, MultiSensor Nasdaq compliance) reduce overhangs. Guidance mostly affirmed/raised (Bunge EPS to $9-9.50, Constellium EBITDA $900-940M), signaling resilience amid macro softness. Key implication: Rotate into AI/industrials outperformers, monitor healthcare/financials for further guide cuts.

23 high priority 27 medium 50 total filings
· daily

Biotech Small-Cap Approvals — April 28, 2026

The April 28, 2026 period captured 10 FDA approvals classified as 'Other' (FALLBACK type), with 0 NMEs, 0 biosimilars, and 0 label expansions, all rated neutral signals at 5/10 strength and materiality. These span diverse sponsors including APOTEX (dual approvals for ASCORBIC ACID), TEVA PHARMS USA INC (BUDESONIDE), CIPLA (ALBUTEROL SULFATE), and others, covering commodity small-molecule generics in respiratory, cardiovascular, GI, psychiatric, and vitamin categories with no dominant therapeutic area clustering. Highest-conviction signal is APOTEX's dual ASCORBIC ACID approvals on 2026-04-21, implying manufacturing redundancy and potential supply positioning in the commoditized vitamin C market but limited by neutral rating and NOT_DISCLOSED commercial metrics. No IRA exposure or exclusivity details provided, underscoring low innovation content. Key risk/watch item: Intensifying generic competition across multiple entrants, potentially pressuring margins in low-barrier segments absent pricing power data.

10 total filings
· daily

Big Pharma Approvals — April 28, 2026

The April 28, 2026 period featured 3 Other approvals (0 NMEs, 0 biosimilars, 0 label expansions) exclusively from big pharma sponsors, delivering uniformly bullish signals with no bearish or neutral readouts. AstraZeneca AB's ANIFROLIMAB-FNIA (SAPHNELO) NME approval emerges as the highest-conviction event at 8/10 strength and materiality, underscoring premium commercial potential via first-in-class exclusivity. Merck Sharp Dohme's PEMBROLIZUMAB (KEYTRUDA QLEX) and Genentech's PERTUZUMAB (PERJETA) label expansions provide steady portfolio extensions at 5/10 each, reinforcing sponsor execution. No dominant therapeutic area theme is evident from the data. Key risk/watch item: absence of disclosed peak sales, exclusivity, pricing power, and market position details limits near-term valuation precision.

3 total filings
· daily

Orphan Drug Approvals — April 28, 2026

The FDA approval period from April 28, 2026 to April 28, 2026 featured 1 orphan drug approval in the 'other' category (0 NMEs, 0 biosimilars, 0 label expansions), signaling modest activity in the sector. Kyowa Kirin's BUROSUMAB-TWZA (CRYSVITA) received a bullish label expansion approval (strength 5/10, materiality 5/10), representing the highest-conviction signal with potential to enhance the sponsor's orphan portfolio despite NOT_DISCLOSED commercial metrics. No dominant therapeutic area theme emerged from the single approval. This event underscores steady execution for Kyowa Kirin in rare diseases, though lacking pipeline breadth. Key risk/watch item: monitor near-term commercial uptake and market position given limited disclosed data.

1 total filings
· daily

New Drug Approvals (Original) — April 28, 2026

The April 28, 2026 FDA approval snapshot features 11 Other approvals (0 NMEs, 0 biosimilars, 0 label expansions per mix, though individual data notes 1 NME and multiple generic-like entries), dominated by neutral generic approvals from sponsors like APOTEX, TEVA PHARMS USA INC, and CIPLA, with no clear therapeutic area clustering. The highest-conviction signal is the bullish NME approval of ANIFROLIMAB-FNIA (SAPHNELO) by ASTRAZENECA AB, signaling a strong commercial entry with high strength (8/10) and materiality (8/10) for their immunology portfolio. These generic approvals (e.g., BUDESONIDE by TEVA PHARMS USA INC, ALBUTEROL SULFATE by CIPLA) are neutral, reflecting commoditized market entries with limited upside or downside absent originator erosion details. Key risk/watch item: Monitor originator revenue impacts from generic entrants like ESCITALOPRAM OXALATE (MICRO LABS) and PANTOPRAZOLE SODIUM (SHUANGCHENG), though no bearish signals flagged.

11 total filings
· daily

Federal Construction & Infrastructure Contracts — April 28, 2026

Fisher Sand & Gravel Co. was awarded an $847,040,000 firm-fixed-price delivery order by U.S. Customs and Border Protection (DHS) for Southwest Border Construction in San Diego, CA, comprising the full obligation in this civilian-only digest (0/1 defense-related). This large-scale infrastructure project underscores DHS/CBP's priority on border facilities under NAICS 236220, providing a bullish signal for construction contractors with a 2.3-year performance period from April 26, 2026, to August 31, 2028. The highest-conviction signal is the significant future revenue stream for Fisher Sand & Gravel Co., estimated at $356M annually. However, high pricing risk inherent in firm-fixed-price terms poses execution challenges. Key watch item: total outlayed progress from current $0 under full and open competition after exclusion of sources.

1 total filings
· daily

DHS Homeland Security Contracts — April 28, 2026

DHS awarded a single $847,040,000 firm fixed price delivery order to Fisher Sand & Gravel Co for Southwest Border Construction in San Diego, CA, representing 100% civilian obligations with 0/1 defense-related contracts. U.S. Customs and Border Protection (CBP) dominates as the agency theme, focusing on commercial and institutional building construction (NAICS 236220) over a 2.3-year performance period from April 26, 2026, to August 31, 2028. The highest-conviction bullish signal is the massive future revenue stream for Fisher Sand & Gravel Co, a non-small business Subchapter S Corporation, under full and open competition after exclusion of sources. Key risk is high pricing/execution risk inherent in the firm fixed price structure with $0 outlayed to date. Investors should watch total outlayed progress and performance milestones toward the 2028 end date.

1 total filings
· daily

New Federal Contractors — April 28, 2026

A single $847,040,000 firm fixed price delivery order awarded to Fisher Sand & Gravel Co by U.S. Customs and Border Protection (DHS) dominates this period's new federal contracts, representing 100% civilian spending with zero defense-related activity. The contract funds SW Border Construction in San Diego, CA, over a 2.3-year performance period from April 26, 2026, to August 31, 2028, signaling robust DHS/CBP infrastructure priorities. Highest-conviction bullish signal for Fisher Sand & Gravel Co as a major future revenue stream in NAICS 236220 commercial building construction. Key risk is high pricing/execution exposure under firm fixed price terms with $0 outlayed to date. Investors should monitor total outlayed progress and performance milestones toward the 2028 end date amid full and open competition dynamics.

1 total filings
· daily

Significant Contract Modifications ($10M+) — April 28, 2026

The single contract in this period represents a $847,040,000 total obligation, entirely civilian with 0/1 defense-related, focused on DHS/CBP border infrastructure. Fisher Sand & Gravel Co secured a firm fixed price delivery order for SW Border Construction in San Diego, CA, spanning April 26, 2026, to August 31, 2028, signaling a major ~$356M annual revenue stream for this non-small business construction firm (NAICS 236220). The highest-conviction bullish signal is the full obligation value under full and open competition after exclusion of sources, providing durable multi-year revenue visibility. A key risk is the high pricing risk inherent in the firm fixed price structure with $0 outlayed to date, vulnerable to cost overruns during the 2.3-year performance period. Watch total outlayed progress and any modifications to the $847M obligation.

1 total filings
· daily

Contract Deobligations Alert — April 28, 2026

A single $847,040,000 firm fixed price delivery order was awarded to Fisher Sand & Gravel Co by U.S. Customs and Border Protection (DHS) for SW Border Construction in San Diego, CA, representing 100% civilian obligations with 0 defense-related contracts. This dominant DHS/CBP infrastructure theme signals a major future revenue stream for the non-small business contractor over a 2.3-year performance period from April 26, 2026, to August 31, 2028. The highest-conviction bullish signal stems from the full and open competition award after exclusion of sources, with no outlays to date. Key watch item is total outlayed progress from the current $0 baseline amid high contract pricing risk on the firm fixed price terms.

1 total filings
· daily

Contract Option Exercises — April 28, 2026

A single $847,040,000 firm fixed price delivery order awarded to Fisher Sand & Gravel Co by U.S. Customs and Border Protection (DHS) dominates this period's contract exercises, representing 100% civilian spending with 0 defense-related awards. The order funds SW Border Construction in San Diego, CA, over ~2.3 years from April 26, 2026, to August 31, 2028, signaling bullish conviction for DHS/CBP infrastructure buildout via full and open competition. Highest-conviction signal is the massive future revenue stream for Fisher Sand & Gravel Co, estimated at $356M annually. Key risk is high pricing/execution exposure under firm fixed price terms with $0 outlayed to date, warranting close monitoring of spending progress.

1 total filings
· daily

Mega Contracts Monitor ($100M+) — April 28, 2026

A single mega contract totaling $847,040,000 was awarded to Fisher Sand & Gravel Co by U.S. Customs and Border Protection (DHS) for Southwest Border Construction in San Diego, CA, representing 100% civilian obligations with 0/1 defense-related. This firm fixed price delivery order, spanning April 26, 2026, to August 31, 2028, signals strong bullish conviction (8/10 strength, 9/10 materiality) for DHS/CBP infrastructure expansion in border facilities (NAICS 236220). The award under full and open competition after exclusion of sources provides Fisher Sand & Gravel Co an estimated $356M annual revenue stream over ~2.3 years. Key risk includes high pricing risk inherent to firm fixed price terms with $0 outlayed to date. Investors should watch total outlayed progress and performance milestones toward the 2028 end date.

1 total filings
· daily

High-Value Federal Grants ($5M+) — April 28, 2026

A single high-value civilian federal contract totaling $847,040,000 was awarded to Fisher Sand & Gravel Co by U.S. Customs and Border Protection (DHS) for Southwest Border Construction in San Diego, CA, representing 100% civilian obligations with 0/1 defense-related. This firm fixed price delivery order, spanning April 26, 2026, to August 31, 2028, signals strong bullish conviction (8/10 strength, 9/10 materiality) for DHS/CBP infrastructure spending in non-building facilities (PSC Y1PZ). The award under full and open competition after exclusion of sources highlights a significant ~$356M annual revenue estimate for the Tempe, AZ-based non-small business contractor in commercial and institutional building construction (NAICS 236220). Key watch item: monitor total outlayed progress from current $0 and performance milestones toward the 2028-08-31 end date amid high pricing risk on the firm fixed price structure.

1 total filings
· daily

General Federal Contracts — April 28, 2026

A single high-materiality $847,040,000 firm fixed price delivery order was awarded to Fisher Sand & Gravel Co by U.S. Customs and Border Protection (DHS/CBP) for Southwest Border Construction in San Diego, CA, representing 100% civilian obligations with zero defense-related activity. This contract underscores a dominant theme of DHS border infrastructure investment, providing Fisher Sand & Gravel—a non-small business Subchapter S Corporation—with a significant ~$356M annualized revenue estimate over its 2.3-year performance period from April 26, 2026, to August 31, 2028. The highest-conviction bullish signal is the full obligation value under full and open competition after exclusion of sources, signaling strong future revenue visibility for construction (NAICS 236220). However, high pricing risk on the firm fixed price structure and zero outlay to date introduce execution uncertainty. Investors should watch total outlayed progress and performance milestones as key indicators of contract realization.

1 total filings
· daily

S&P 500 Technology Sector SEC Filings — April 28, 2026

Across 27 filings in the USA S&P 500 Technology intelligence stream, a dominant theme emerges from multiple 13F-HR disclosures showing overwhelming institutional conviction in core tech names like Nvidia, Broadcom, Apple, Amazon, and Alphabet, with top holdings exceeding $1B in several portfolios and tech/semicon comprising 20-40% of allocations. Non-tech filings reveal mixed results: REITs like AvalonBay posted 40% YoY EPS growth but FFO declines and expense inflation, while banks such as Camden National surged 200% YoY net income amid deposit growth yet faced QoQ NIM compression of 5 bps. Forward-looking catalysts cluster in May 2026 (SPAC merger vote/close) and EOY 2026 (biotech trial data), with capital returns strong via $198M AvalonBay buybacks and Camden repurchases/dividends. Tech-specific signals include director departures at Intuit and Ribbon Communications (high risk), Knowles 10-Q metrics pending deeper review, and institutional passives overweighting growth tech/ETFs. Portfolio-level trends highlight tech resilience amid broader sector volatility, with 5/7 detailed earnings showing YoY beats but QoQ softening (avg net income -3% linked quarter). Actionable now: overweight tech on institutional flows, monitor SPAC redemptions and REIT guidance tweaks for relative outperformance.

11 high priority 16 medium 27 total filings
· daily

Nasdaq 100 Stocks SEC Filings — April 28, 2026

Across 37 SEC filings from NASDAQ-100 constituents and related entities on April 28, 2026, dominant themes include mixed Q1 2026 results for REITs and regional banks—strong YoY EPS growth (AvalonBay +40.4%, Camden National +200%) offset by QoQ declines, margin compression (NIM -5 bps, op ex +4.7%), and elevated expenses—amid ongoing developments and capital returns. Biotech/pharma shines with Immunic's CMO appointment advancing phase 3 MS trials (data E2026) and Gilead's $7.1B Arcellx acquisition completion (77.2% tendered at $115/share + CVR). SPAC activity peaks with AParadise merger deadlines (Apr 29 non-redemption, May 1 vote, May 7 close), while 13F filings reveal institutional tech overweight (e.g., Fukoku's $195M Broadcom, National Mutual's $89M Nvidia). Capital allocation favors buybacks (AvalonBay $198M, Camden 33k shares) and dividends, with REIT Net Debt/EBITDA ~4.8x and bank CET1 >12%. Portfolio trends flag REIT NOI stagnation (AvalonBay +0.2%), bank deposit growth (Camden +1% QoQ), and M&A upside (Arcellx CVR to 2030). Actionable implications: Biotech catalysts for alpha, SPAC arbitrage near-term, caution on REIT expense trends and director departures (Intuit, Ribbon).

14 high priority 23 medium 37 total filings
· daily

US Activist Hedge Fund Institutional SEC 13D 13G — April 28, 2026

Across the single filing in the Activist & Institutional Activity stream, Vanguard Capital Management LLC disclosed a passive beneficial ownership of 7,985,349 shares (7.22%) in lululemon athletica inc. (LULU) via Schedule 13G filed on April 28, 2026, reflecting holdings as of March 31, 2026, with neutral sentiment and materiality rated 7/10. This passive investment under Rule 13d-1(b) signals institutional conviction in LULU without activist intent, potentially stabilizing the shareholder base amid US equity markets. No period-over-period comparisons, forward-looking statements, insider trading activity, capital allocation details, M&A transactions, financial ratios, or operational metrics were present in the enriched data, limiting trend synthesis to ownership disclosure alone. The filing certifies holdings in the ordinary course of business, highlighting no purpose to change control. Portfolio-level implications point to growing passive institutional interest in consumer discretionary/apparel, though single-filing limits cross-company patterns. Key market takeaway: monitor for follow-on 13D conversions or peer institutional moves signaling sector conviction.

1 medium 1 total filings
· daily

S&P 500 Financials Sector SEC Filings — April 28, 2026

Across 50 filings from S&P 500 Financials and related sectors on April 28, 2026, Q1 2026 earnings dominate with 20+ companies reporting average revenue growth of 12% YoY (e.g., PJT Partners +29%, Bread Financial +6% NII), but profitability mixed as 8/15 showed net losses or declines due to higher costs/fuel (e.g., JetBlue op loss -10% margin, Shutterstock -18% rev). Margin trends split: expansions in 6/12 (Bread NIM +119bps, Polaris GP +423bps) vs compressions in 5/12 (Allegion -200bps adj). Capital allocation robust with $1B+ buybacks (PJT $244M, Pentair $200M, American Tower $184M) and dividend hikes (Pentair 50th year +8%, Enterprise +2.8%). M&A catalysts abound (RE/MAX merger, Ligand/XOMA accretive, CECO/Thermon June close), with 7/10 guidances raised (Centene EPS >$3.40, Curbline OFFO $1.20-1.23). Insider conviction mixed (high ownership Lindblad 26%), 13Fs show tech-heavy tilts (China Universal NVIDIA top). Portfolio trend: Resilient growth amid costs, bullish forward outlooks signal upside for cyclicals/financials.

17 high priority 33 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — April 28, 2026

Across 50 filings in the USA S&P 500 Consumer Staples intelligence stream (with broader cross-sector insights), key themes include modest revenue growth averaging 5-10% YoY in staples like beverages (CCEP +6.7%, KO +12%) offset by pricing/margin pressures (KMB gross margin -60bps, UPS US Domestic rev -2.3%), mixed sentiments in 60% of detailed reports, and positive volume drivers (CCEP +8.5% unit cases, KO +3%). Capital allocation favors shareholder returns with buybacks (Valmont $57.5M, Asbury $147M) and dividend hikes (First Commonwealth +3.7%), while forward guidance shows resilience (Omnicell raised FY EBITDA to $153-168M, GM raised FY EBIT to $13.5-15.5B). Outliers include strong international growth (KMB Intl Personal Care +9.1%) amid US softness, and neutral institutional 13F holdings signaling stability. Portfolio-level trends highlight margin compression in 4/7 earnings reports (avg -100bps) but operating leverage in others (Valmont op inc +21.3%), implying defensive positioning in staples amid economic uncertainty. Critical developments like KO value share gains and Omnicell 15% rev growth offer near-term catalysts, while risks from originations declines (GM Financial -15% YoY) warrant caution.

14 high priority 36 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — April 28, 2026

Across 50 SEC filings from S&P 500 Industrials and related streams dated April 28, 2026, Q1 2026 results reveal mixed performance with transportation/industrials showing revenue resilience (e.g., ArcBest +3.2% YoY to $998.8M, Avery Dennison +7% to $2.3B) amid tonnage/shipment growth but margin pressures (ArcBest OR 97.3% vs 95.9%, UPS U.S. Domestic op profit -47% to $515M). Biotech/pharma subsets shone with guidance raises (Ligand rev to $270-310M post-XOMA acquisition, Axogen 20%+ FY growth) and catalysts (Rocket $180M PRV sale), while media/real estate faced headwinds (Shutterstock rev -18% YoY, reAlpha -9%). Capital allocation remains shareholder-friendly with $860M returns at Hilton, $133M at Avery, UPS $5.4B FY dividends; 13F filings highlight institutional tech/ETF bias (e.g., China Universal NVIDIA $81M top). Overarching themes include accretive M&A (Ligand, Real Brokerage scaling agents 5x), cost savings (UPS $600M Q1), and pending regulatory hurdles (Shutterstock-Getty CMA deadline June 14). Portfolio-level trends: 7/12 earnings reporters posted YoY rev growth averaging +10% but 5 saw op margin compression (-150bps avg); forward catalysts cluster in H2 2026 (deal closes, trials). Implications: Tactical buys in growth industrials/biotech, caution on volume-dependent transports amid softening demand.

14 high priority 36 medium 50 total filings